Brentuximab Vedotin
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
... Brentuximab vedotin is an effective therapy for patients with relapsed or refractory ...imab vedotin shows its advantages, and it is a very prom- ising agent in the treatment of relapsed or ...
5
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
... of brentuximab vedotin for malignant ...existed. Brentuximab vedotin was generally well-tolerated by patients reported in the included studies; adverse effects also occurred, but they were ...
7
A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin
... Notes: (A) The arrow points to Hodgkin lymphoma cells expressing CD30. The image was obtained by staining CD30 when the disease was diagnosed in May 2012. (B) The arrow points to Hodgkin Reed–Sternberg cells surrounded ...
9
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
... promising. Brentuximab vedotin is an ADC composed of an anti-CD30 antibody linked to a potent microtubule-disrupting agent monomethyl auristatin E ...CD30, brentuximab vedotin is internalized ...
12
<p>Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma</p>
... BV, brentuximab vedotin; cAC10, chimeric anti-CD30 monoclonal antibody; cHL, Classic Hodgkin lymphoma; CMR, complete metabolic response; CR, complete response; CTLA-4, cytotoxic T lymphocyte antigen 4; ...
17
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
... patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with ...
8
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
... Background: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two ...
8
Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature
... HIV-associated HL are EBV-positive [4, 6]. The precise mechanism by which EBV contributes to development of HL remains unclear. EBV infection has no influence on the prognosis of children with HL [7]. However, some ...
6
Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma
... ited. Brentuximab vedotin is an immunotoxin targeting CD30-expressing cells, including those in Hodgkin lymphoma ...and brentuximab vedotin are better tolerated with less ...and/or ...
5
Preliminary Economic Evaluation of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: An "Early Look" Model Based on Phase II Results
... Results of the pivotal phase II trial were consistent and verified the initial findings from the phase I trial [14]. A total of 102 patients with the median age of 31 years received a brentuximab vedotin ...
108
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
... The goal of targeted immunotherapy in cancer is to damage both malignant and tumor-supporting cells of the microenvironment but spare unaffected tissue. The malignant cells in classical Hodgkin lymphoma (cHL) selectively ...
13
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
... with brentuximab vedotin achieved CR and subsequently received an allo- geneic ...with brentuximab vedotin com- bined with CHOP and then relapsed; retreatment with brentuximab ...
8
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
... allow brentuximab vedotin to be integrated into multiagent chemotherapy regimens, either in addition to or instead of other drugs, creating a new more efficacious and less toxic treatment ...of ...
9
<p>The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma</p>
... there was no antitumor activity seen. 7 Phase I and II studies of the chimeric anti-CD30 mAb, SGN-30, demon- strated tolerability, but lacked clinical activity. 8,9 The human anti-CD30 mAb, MDX-060, performed slightly ...
9
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
... Abstract: Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting ...
7
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
... conjugate, brentuximab vedotin, and classical lymphoma salvage regimen DHAP (cisplatin, high-dose cytarabine and dexamethasone) was ...conjugate brentuximab vedotin and a classical regimen ...
5
Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
... The median number of brentuximab vedotin cycles was five (range 1–18). The response and survival outcomes are summarized in Table 2. Of the 22 patients in the study, one patient (4.5%) was not evaluable for ...
6
Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma
... therapy. Brentuximab vedotin (BV), which is an antibody-drug conjugate that targets CD30, demonstrated sustained res- ponses in patients with recurrent ALCL and had a very moderate adverse-effect profile ...
8
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
... the brentuximab vedotin plus ABVD combination produced a high rate of pulmonary toxicity (44%) [29], suggesting intolerance and infeasibility for further ...compared brentuximab vedotin plus ...
14
What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO)
... BV, brentuximab vedotin; CAR, chimeric antigen receptor; CTL, cytotoxic T lymphocyte; DCR, disease control rate; DLBCL, diffuse large-cell B lymphoma; DOR, duration of response; EBV, Epstein- Barr virus; ...
14